Neos Therapeutics NASDAQ: NEOS
Neos Therapeutics is focused on developing, manufacturing, and commercializing innovative extended-release products that utilize our proprietary modified-release drug delivery technology platform
Name | Neos Therapeutics |
Ticker | NEOS |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Drug Manufacturers -Specialty Pharma |
Price | 0.93 |
52W Low/High | 0.47 / 1.88 |
Market cap | 46 M |
1Y Total Return |
-50.37%
Weak |
1Y Volatility |
105.74%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Neos Therapeutics is focused on developing, manufacturing, and commercializing innovative extended-release products that utilize our proprietary modified-release drug delivery technology platform
Details
Ticker | NEOS |
Name | Neos Therapeutics |
ISIN | US64052L1061 |
CUSIP | |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Drug Manufacturers -Specialty Pharma |
Country | USA |
Currency | U.S. Dollar |
In Index(ices) | NASDAQ Biotechnology Index |
Share as of 1/26/21
Close Price | 0.93 |
52W Low/High | 0.47 / 1.88 |
Market cap | 46 M |
1Y Total Return |
-50.37%
Weak |
1Y Volatility |
105.74%
High Risk |
Beta | 1.80 |
PE (trailing) | - |
12M Dividends | - |
Last Dividend Date | - |
Dividend Yield | - |
Fin. Strength
Net Profit Margin | -38.4% |
Cash from Op. / Cur. Liabilities | -0.10 |
Diluted Earnings / Share | -0.44 |
ROE | - |
ROIC | - |
Price / Revenue | 0.8 |
Price / Book | -2.3 |
Price / CF | -7.2 |
Current Ratio | 0.7 |
Cur.Liabilities / Tot.Liabilities | 0.8 |
Financial Leverage | - |
in Mils USD |
rolling-year up to September
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
57
|
63
|
44
|
22
|
7
|
3
|
|
Gross Profit |
32
|
38
|
21
|
8
|
-
|
-
|
|
R&D |
6
|
9
|
8
|
11
|
11
|
11
|
|
EBITDA |
-10
|
-11
|
-43
|
-58
|
-65
|
-20
|
|
Operating Income |
-13
|
-16
|
-47
|
-62
|
-68
|
-22
|
|
Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
per Share | |||||||
Diluted avg Shares |
50
|
50
|
30
|
28
|
16
|
12
|
|
EPS exc. Extra |
-0.44
|
-0.42
|
-1.88
|
-3.39
|
-3.38
|
-23.52
|
|
Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
65
|
92
|
73
|
113
|
97
|
131
|
|
Cash, Eq & Invt ShortTerm |
13
|
25
|
17
|
66
|
60
|
103
|
|
Total Current Assets |
44
|
68
|
50
|
88
|
72
|
106
|
|
Total Non-Current Assets |
21
|
24
|
23
|
25
|
25
|
25
|
|
Intangibles |
11
|
13
|
15
|
17
|
16
|
17
|
|
Total Liabilities |
85
|
95
|
100
|
98
|
82
|
44
|
|
Total Current Liabilities |
67
|
61
|
53
|
36
|
21
|
13
|
|
Long Term Debt |
18
|
34
|
46
|
62
|
60
|
31
|
|
Shareholder equity |
-21
|
-3
|
-27
|
15
|
16
|
87
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
-6
|
-17
|
-51
|
-58
|
-62
|
-19
|
|
Depreciation |
4
|
4
|
3
|
3
|
3
|
3
|
|
Cash from Investing |
1
|
-3
|
22
|
-6
|
-21
|
2
|
|
Capex |
1
|
1
|
1
|
3
|
4
|
1
|
|
Cash from Financing |
-6
|
27
|
3
|
64
|
23
|
109
|
|
Stock Issued |
0
|
43
|
4
|
65
|
0
|
101
|
|
Debt (LT) Issued |
-6
|
-16
|
-1
|
-1
|
23
|
8
|
|
Free Cash Flow |
9
|
-16
|
-22
|
-63
|
-85
|
-
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
Current Ratio |
0.7
|
1.1
|
0.9
|
2.4
|
3.4
|
8.0
|
|
Financial Leverage D/E |
-
|
-
|
-
|
4.48
|
3.88
|
0.39
|
|
Return on Capital Avg |
-
|
-274.3%
|
-253.3%
|
-183.4%
|
-287.5%
|
-314.2%
|
|
Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available